Floatz logo

Tak-500

Mesothelioma

TakedaPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

55 Active assets in the Mesothelioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
Orion Corporation, Orion Pharma
Phase 2B
Fludarabine
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Genmab
Phase 2B
18f-fspg
Andrei Iagaru
Phase 2B

View all 50 →

Same molecule, other indications

Tak-500 is also rated in:

head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
nasopharyngeal carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →